ArticleNature communications2023
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
21.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- GDF-15 as a biomarker for diagnosis and prognosis of lung cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- A systematic review of the neuroprotective role and biomarker potential of GDF15 in neurodegeneration.Frontiers in immunology · 2024Pooled it
- Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.Journal of hematology & oncology · 2026Trial
- First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.Cancer research communications · 2025Trial
- Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.Journal for immunotherapy of cancer · 2025Trial
- Trial
- The causes of cachexia: key signals and the brain.Nature reviews. Endocrinology · 2026Review
- Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab.Journal of gastrointestinal cancer · 2026Article
- Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.Cell reports. Medicine · 2026Article
- GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma.Cancer research · 2026Article
- GDF15: A Hijacked Metabo-Hormone Orchestrating Cachexia and Immunosuppression in Cancer.Biomolecules · 2026Review
- GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential.Biomolecules · 2026Review
- Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.Cell discovery · 2026Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- Human brain pericytes protect the blood-brain barrier from triple-negative breast cancer cells while promoting tumor aggressiveness.Journal of cell communication and signaling · 2026Article
- Article
- Research progress on the biological function and molecular mechanism of GDF-15 in solid malignant tumors.World journal of surgical oncology · 2026Review
- The effects of tissue inflammation on cancer cachexia.Biochimica et biophysica acta. Molecular basis of disease · 2026Review
- Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113).ESMO gastrointestinal oncology · 2026Article
- A GDF-15-GFRAL axis controls autoimmune T cell responses during neuroinflammation.Nature immunology · 2026Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors at 13 institutions in 6 countries.
Markus HaakeDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.ORCID 0009-0008-3353-7919
Beatrice HaackDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Tina SchäferDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Patrick N HarterGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Greta MattavelliMildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg, Germany.
Patrick EiringDepartment of Biotechnology and Biophysics, Julius Maximilians University Würzburg, Am Hubland, 97074, Würzburg, Germany.
Neha VashistDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Florian WedekinkDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Sabrina GensslerCatalYm GmbH, Am Klopferspitz 19, 82152, Munich, Germany.
Birgitt FischerDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Julia DahlhoffDepartment of Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Fatemeh MokhtariDepartment of Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Anastasia KuzkinaDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Marij J P WeltersDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.ORCID 0000-0002-9809-8266
Tamara M BenzDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Lena SorgerDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0002-6959-3823
Vincent ThiemannDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Giovanni AlmanzarDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Martina SelleDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Klara TheinDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Jacob SpäthDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.ORCID 0009-0003-0293-6494
Maria Cecilia GonzalezCatalYm GmbH, Am Klopferspitz 19, 82152, Munich, Germany.
Carmen ReitingerDivision of Genetics, Department of Biology, University of Erlangen, 91058, Erlangen, Germany.ORCID 0000-0003-0515-5119
Andrea Ipsen-EscobedoDivision of Genetics, Department of Biology, University of Erlangen, 91058, Erlangen, Germany.
Kilian Wistuba-HamprechtDepartment of Dermatology, University Medical Center Tübingen, Tübingen, Germany.ORCID 0000-0002-3104-8512
Kristin EichlerDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Katharina FilipskiGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pia S ZeinerGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Rudi BeschornerDepartment of Neuropathology, University of Tübingen, Tübingen, Germany.ORCID 0000-0003-1109-915X
Renske GoedemansDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.
Falk Hagen GogollaInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innrain 80, 6020, Innsbruck, Austria.
Hubert HacklInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innrain 80, 6020, Innsbruck, Austria.ORCID 0000-0003-4055-3841
Rogier W RooswinkelForbion, Naarden, The Netherlands.
Alexander ThiemDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-9504-4281
Paula Romer RocheDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Hemant JoshiDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-7151-359X
Dirk PühringerDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Achim WöckelDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Joachim E DiessnerDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Manfred RüdigerCatalYm GmbH, Am Klopferspitz 19, 82152, Munich, Germany.ORCID 0000-0002-1940-0878
Eugen LeoCatalYm GmbH, Am Klopferspitz 19, 82152, Munich, Germany.
Phil F ChengDepartment of Dermatology, University of Zurich, University of Zurich Hospital, Wagistrasse 18, 8952, Zürich, Switzerland.ORCID 0000-0003-2940-006X
Mitchell P LevesqueDepartment of Dermatology, University of Zurich, University of Zurich Hospital, Wagistrasse 18, 8952, Zürich, Switzerland.ORCID 0000-0001-5902-9420
Matthias GoebelerDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-7095-9848
Markus SauerDepartment of Biotechnology and Biophysics, Julius Maximilians University Würzburg, Am Hubland, 97074, Würzburg, Germany.ORCID 0000-0002-1692-3219
Falk NimmerjahnDivision of Genetics, Department of Biology, University of Erlangen, 91058, Erlangen, Germany.ORCID 0000-0002-5418-316X
Christine Schuberth-WagnerCatalYm GmbH, Am Klopferspitz 19, 82152, Munich, Germany.
Stefanie von Feltenoikostat GmbH, Statistical Analyses and Consulting, Lucerne, Switzerland.ORCID 0000-0002-5264-6394
Michel MittelbronnDepartment of Oncology (DONC), Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg.ORCID 0000-0002-2998-052X
Matthias MehlingDepartment of Biomedicine and Neurology Department, University Hospital Basel, 4031, Basel, Switzerland.
Andreas BeilhackDepartment of Medicine II, University Hospital of Würzburg, Würzburg, Germany.ORCID 0000-0002-3165-2648
Sjoerd H van der BurgDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.
Angela RiedelMildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg, Germany.
Benjamin WeideDepartment of Dermatology, University Medical Center Tübingen, Tübingen, Germany.
Reinhard DummerForbion, Naarden, The Netherlands.ORCID 0000-0002-2279-6906
Jörg WischhusenDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany. Wischhusen_J@ukw.de.ORCID 0000-0002-0390-4297
Universitätsklinikum Würzburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGoethe University Frankfurt · DELeiden University Medical Center · NLInnsbruck Medical University · ATUniversity of Tübingen · DEUniversity of Würzburg · DEUniversity of Zurich · CHBernstein Center for Computational Neuroscience Tübingen · DECentre Hospitalier de Luxembourg · LUPrevention Institute · USUniversity Hospital of Basel · CHWashington University in St. Louis · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don't respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.
Indexed as
MelanomaT-LymphocytesAnimalsEndothelial CellsHumansImmune Checkpoint InhibitorsImmunotherapyLymphocyte Function-Associated Antigen-1MiceTumor MicroenvironmentImmune Checkpoint InhibitorsLymphocyte Function-Associated Antigen-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.